Literature DB >> 10926873

Role for G(12)/G(13) in agonist-induced vascular smooth muscle cell contraction.

A Gohla1, G Schultz, S Offermanns.   

Abstract

Receptor-induced vascular smooth muscle cell contraction is mediated by dual regulation of myosin light chain (MLC(20)) phosphorylation through Ca(2+)-dependent stimulation of myosin light chain kinase and Rho/Rho-kinase-mediated inhibition of myosin phosphatase. Although myosin light chain kinase regulation is initiated by the coupling of receptors to G proteins of the G(q) family, G(q) and G(11), it is not known how receptors regulate the Rho/Rho-kinase-mediated pathway. In vascular smooth muscle cells, receptor-mediated MLC(20) phosphorylation and cell contraction was blocked by inhibitors of each of the pathways. Receptors of various vasocontractors were found to couple to G(q)/G(11) and G(12)/G(13), and constitutively active forms of G alpha(12) and G alpha(13) induced a pronounced contraction of vascular smooth muscle cells that could be blocked by C3 exoenzyme, by inhibition of Rho-kinase, and by stable analogues of cGMP and cAMP. Receptor-mediated smooth muscle cell contraction was strongly inhibited by dominant-negative forms of G alpha(12) and G alpha(13). These data indicate that a G(12)/G(13)-mediated Rho/Rho-kinase-dependent pathway operates in smooth muscle cells and that dual regulation of MLC(20) phosphorylation by vasocontractors is initiated by the dual coupling of their receptors to G proteins of the G(q) and G(12) families.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10926873     DOI: 10.1161/01.res.87.3.221

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  49 in total

Review 1.  Cell signaling of angiotensin II on vascular tone: novel mechanisms.

Authors:  Aurelie Nguyen Dinh Cat; Rhian M Touyz
Journal:  Curr Hypertens Rep       Date:  2011-04       Impact factor: 5.369

2.  Rho kinase activity governs arteriolar myogenic depolarization.

Authors:  Yao Li; Joseph E Brayden
Journal:  J Cereb Blood Flow Metab       Date:  2015-12-07       Impact factor: 6.200

3.  Exercise-induced inhibition of angiotensin II vasoconstriction in human thigh muscle.

Authors:  R Matthew Brothers; Mads L Haslund; D Walter Wray; Peter B Raven; Mikael Sander
Journal:  J Physiol       Date:  2006-09-14       Impact factor: 5.182

4.  Class II phosphoinositide 3-kinase alpha-isoform regulates Rho, myosin phosphatase and contraction in vascular smooth muscle.

Authors:  Yu Wang; Kazuaki Yoshioka; Mohammed Ali Azam; Noriko Takuwa; Sotaro Sakurada; Yuji Kayaba; Naotoshi Sugimoto; Isao Inoki; Takaharu Kimura; Tomoyuki Kuwaki; Yoh Takuwa
Journal:  Biochem J       Date:  2006-03-15       Impact factor: 3.857

Review 5.  Role of G12 proteins in oncogenesis and metastasis.

Authors:  Juhi Juneja; Patrick J Casey
Journal:  Br J Pharmacol       Date:  2009-04-30       Impact factor: 8.739

Review 6.  Regulation and physiological functions of G12/13-mediated signaling pathways.

Authors:  Nobuchika Suzuki; Nicole Hajicek; Tohru Kozasa
Journal:  Neurosignals       Date:  2009-02-12

7.  Mechanism of contractile dysfunction induced by serotonin in coronary artery in spontaneously hypertensive rats.

Authors:  Hao Wang; Xiao-Yan Gao; Fang Rao; Hui Yang; Zhao-Yu Wang; Lin Liu; Su-Juan Kuang; Qi Wu; Chun-Yu Deng; Jing-Song Xu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-01-24       Impact factor: 3.000

8.  p63RhoGEF couples Gα(q/11)-mediated signaling to Ca2+ sensitization of vascular smooth muscle contractility.

Authors:  Ko Momotani; Mykhaylo V Artamonov; Darkhan Utepbergenov; Urszula Derewenda; Zygmunt S Derewenda; Avril V Somlyo
Journal:  Circ Res       Date:  2011-09-01       Impact factor: 17.367

Review 9.  Heterotrimeric G protein signaling in polycystic kidney disease.

Authors:  Taketsugu Hama; Frank Park
Journal:  Physiol Genomics       Date:  2016-05-13       Impact factor: 3.107

Review 10.  p63RhoGEF: a new switch for G(q)-mediated activation of smooth muscle.

Authors:  Ko Momotani; Avril V Somlyo
Journal:  Trends Cardiovasc Med       Date:  2012-08-16       Impact factor: 6.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.